Company intelligence / Profile preview

Cytokind

Ownership: Private
Development stage: Phase 2

Overview

Cytokind has developed FDA-cleared narrowband UVB phototherapy devices for dermatological conditions such as psoriasis, with clinical evidence supporting reduced inflammation and improved outcomes. The company is translating this technology to treat broader autoimmune disorders, including MS, GvHD, and COVID‑19-related inflammation. Early clinical data suggest a reduction in relapses by 30% in MS patients using UVB treatment. Ongoing research includes biomarker discovery and systemic immune stabilization across multiple inflammatory diseases[1][3].

Therapeutic areas: DermatologyImmunologyNeurologyInfectious Diseases
Modalities: DevicePhototherapy (Narrowband UVB light therapy)
Industry: Therapeutic Medical Devices

Partnerships

Not explicitly listed; some collaborations with academic researchers are implied through sponsored studies[1].

Beyond the preview

Go deeper on Cytokind.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytokind.

Explore the full profile